The FDA approved an intravenous (IV) formulation of fosfomycin (Contepo) to treat adults with complicated urinary tract ...
UCB has announced FDA’s approval of Kygevvi (doxecitine and doxribtimine) for the treatment of adults and pediatric patients ...
MedPage Today on MSN
Ultra-Rare Mitochondrial Disease Gets First FDA-Approved Drug
T he FDA approved doxecitine and doxribtimine powder (Kygevvi) for thymidine kinase 2 deficiency (TK2d), an ultra-rare ...
UCB has scored an FDA approval for ultra-rare disease treatment Kygevvi, continuing the positive momentum for the Belgian ...
In October 2025, the U.S. Food and Drug Administration (FDA) granted approval to multiple new cancer therapies and supportive ...
GlobalData on MSN
FDA approves UCB’s Kygevvi for genetic mitochondrial disease
The approval was based on data from a Phase II trial, two retrospective chart review studies and an expanded access programme ...
Rybelsus is now FDA-approved for managing cardiovascular health. Doctors say oral GLP-1s may reduce heart attack and stroke ...
A groundbreaking FDA approval offers the first-ever treatment for ultra-rare Thymidine Kinase 2 Deficiency (TK2d). KYGEVVI, a ...
FDA approves cancer drug belantamab mafodotin-blmf for relapsed multiple myeloma in combination with bortezomib and dexamethasone.
Elinzanetant belongs to a new class of drugs designed to target what is believed to be a key mechanism responsible for ...
A biotech stock with strong FDA approval odds this November may see limited upside amid a full valuation and a pending lawsuit.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback